Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06735391 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

StatusRecruiting
PhasePhase 3
Started2024-10-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2024 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.
Trial Details
NCT Number NCT06735391
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
Enrollment 516 participants
Start Date 2024-10-23
Primary Completion 2026-09-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-16